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Abstract
Aims
B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) predict cardiovascu-
lar endpoints in patients and all-cause death in the general population. This was assigned
to their association with clinical cardiac remodelling defined as changes in size, shape and
function of the heart. The aim of this study was to evaluate whether NT-proBNP and BNP
were associated with cardiovascular and overall death independent of clinical cardiac
remodelling measured by echocardiography as left ventricular hypertrophy (LVH), diastolic
dysfunction and left ventricular ejection fraction (EF).
Methods and Results
In a general population-based cohort study from Germany (KORA-S3) with subjects’ base-
line age ranging from 25 to 74 years, cardiac morphology and function were assessed as
left ventricular mass (LVM), diastolic dysfunction and EF by echocardiography and circulat-
ing NT-proBNP and BNP were measured at baseline. In 1,223 subjects with mortality fol-
low-up information, we examined the association of baseline NT-proBNP and BNP with
cardiovascular mortality (number of deaths = 52, median follow-up time = 12.9years) using
Cox regression without and with adjustment for cardiovascular risk factors, LVM, diastolic
dysfunction and EF. The risk of cardiovascular mortality increased with higher NT-proBNP
levels measured at baseline (hazard ratio HR = 1.67 per unit increment in logNT-proBNP, p
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= 2.78*10−4, adjusted for age and sex). This increased risk persisted after adjustment for
cardiovascular risk factors, LVM, diastolic dysfunction and EF (HR = 1.73; p = 0.047).
When excluding subjects with relevant LVH (LVM to body surface area > 149g/m2 in men /
122g/m2 in women), the NT-proBNP association with mortality was still significant (n =
1,138; number of deaths = 35; HR = 1.48; p = 0.04). We found similar results for BNP.
Conclusion
Our data confirms NT-proBNP and BNP as predictor of cardiovascular mortality in a large
general population-based study with long-term follow-up. Our study extends previously
published population-based studies to younger and potentially healthier individuals without
relevant LVH, diastolic dysfunction or LVD.
Introduction
B-type natriuretic peptide (BNP) and its equimolarly secreted,more stable N-terminal cleavage
product NT-proBNP are increasingly accepted as biomarkers for heart failure: High levels are
used for diagnosis of heart failure in emergency units and decreasing levels may indicate treat-
ment success in heart failure patients [1]. Also for the general population, BNP and NT-
proBNP are known to reflect cardiac morphology and function as assessed by left-ventricular
mass (LVM) and left-ventricular ejection fraction (EF)[2].
Plasma NT-proBNP and BNP levels have already been shown to predict mortality in the
general population. In studies like the Framingham Offspring collective [3], the Olmsted
County survey[4] and the PREVEND study [5], higher levels of BNP and NT-proBNP at base-
line were associated with early all-cause mortality and cardiovascular events in a median fol-
low-up of 5.2 to 7.5 years. These findings have given rise to a lively debate: Is BNP and NT-
proBNP predictingmortality solely due to the fact that BNP and NT-proBNP monitor preclini-
cal cardiac processes [6] or are these natriuretic peptides additionally marker of extra-cardiac
diseases, as proposed by several recent studies [7–9]. It remains an unsettled issue whether
bloodNT-proBNP levels solely reflect cardiac processes or also have a role independent of car-
diac remodelling.
In the case of any direct association of BNP on mortality independent of cardiac remodel-
ling, at least a part of the association of BNP (or NT-proBNP) with mortality should be inde-
pendent of measures of cardiac remodelling. In published literature, cardiac remodelling
processes [10,11] are complex, interrelated and chamber-specific at the molecular and cellular
level. These complex processes manifest clinically. As stated by the International Forum on
Cardiac Remodeling [12] and further on commonly accepted [13] and implemented in current
guidelines [14,15], clinical cardiac remodelling is precisely defined as changes in size, shape
and function of the heart. Common effective echocardiographicmeasures of such processes are
LVM, signs of diastolic dysfunction and EF [12,14,16]. Therefore, a direct role of BNP on mor-
tality independent of cardiac morphology and function can be supported by showing that the
association of NT-proBNP levels with mortality persists after adjusting for LVM, diastolic dys-
function and EF in general-population studies. However, only two epidemiological studies
with measurements of BNP or NT-proBNP and echocardiography at baseline are currently
available reporting follow-up periods of less than six years[3,4]. The aim of our current investi-
gation was to evaluate whether NT-proBNP and BNP were associated with long-term cardio-
vascular or overall death independent of clinical cardiac remodellingmeasured as left
NT-proBNP as Independent Predictor of Mortality
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ventricular hypertrophy (LVH), diastolic dysfunction and left ventricular ejection fraction
(EF).We report on our data from the longitudinal general population-basedKORA-S3 study
(CooperativeHealth Research in the Region of Augsburg, Germany), which thoroughly
assessed cardiac morphology and function by echocardiography at baseline and provides a
unique long-term follow-up of up to 13 years.
Methods
Study sample
The echocardiographic study of the German population-basedKORA platform (Cooperative
Health Research in the Region of Augsburg) was recruited from the third survey (S3) con-
ducted 1994/95. Its design has been described in detail previously [17–20]. Briefly, the study
included 1,675 subjects (response 75%) [21] aged 25 to 74 years at baseline based on recruit-
ment from local registries in and around the middle-size cite of Augsburg, Bavaria. Inclusion
criteria were a German passport as well as the ability and willingness to provide informed con-
sent. For this investigation, we excluded 452 attendees (unavailable baseline NT-proBNP val-
ues, 243 subjects; missing follow-up data, 2 subjects; insufficientM-mode tracings at baseline,
207 subjects) yielding 1,223 for this analysis.
Ethics statement
The Ethics Committee of the Bavarian Medical Association (Bayerische Landesärztekammer)
and the Bavarian commissioner for data protection and privacy (Bayerischer Datenschutz-
beauftragter) approved the study. All study participants provide written consent after being
informed about the study. All subjects have the option to restrict their consent to specific pro-
cedures, e. g. by denying storage of biosamples.
General data assessment
Socio-demographic status was examined in a standardized face-to-face interview. The presence
of arterial hypertension was defined in line with the recently published scientific statement
[22] of the American Heart Association as resting systolic blood pressure> 140mmHg and/or
diastolic blood pressure> 90mmHg and/or current antihypertensive drug therapy. Diabetes
mellitus was established as intake of oral antihyperglycaemic agents or insulin and/or a gly-
cated haemoglobin (HbA1c) level equal or above 6.5% as recommended by the American Dia-
betes Association[23].
Assessment of cardiac morphology and function by echocardiography
A standardized transthoracic echocardiography was performed in strict accordance with the
recommendations of the American Society of Echocardiography (ASE) [24].
LVM was calculated by Devereux formula and analysed in relation to the individual body
surface area as approximated by DuBois’ formula [25] (LVMi). For probing purposes, two cut-
points for LV hypertrophy were explored. Any left ventricular hypertrophy (LVH) was defined
as left ventricularmass to body surface area> 115g/m2 for men or> 95g/m2 for women,
respectively. The cut-off for relevant left ventricular hypertrophy was set to LVMi > 149g/m2
(men) / 122g/m2 (women) according to the current American and European guidelines [26].
Left atrial (LA) volume was determined according to current guidelines [26] as published
elsewhere [27]. The end-systole, blood-tissue interface of the left atrium was traced on the api-
cal four-chamber view. The area under the mitral valve and the inflow of the pulmonary veins
were excluded. The volume was calculated using the method of discs (the Simpsons rule)[26].
NT-proBNP as Independent Predictor of Mortality
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LA volume was indexed to body surface area (LAVi). LAVi > 34ml/m2 defined left atrial
enlargement. Peak E–and A-wave velocities of the transmitral flow profile were determined
with a PWDoppler sample volume between the tips of the mitral valve leaflets in the apical
four-chamber-view. Mitral E/A ratio< 0.75 determined early diastolic dysfunction[28].
Since measurements of LV function by mono- or biplane volumetry (Simpson) were not
available in all individuals, the Teichholz formula [29] was used for quantification of left ven-
tricular ejection fraction (EF). EF< 55% was considered as systolic left ventricular dysfunction
(LVD) [30].
Cardiovascular death
The outcome analysed in this study was mortality from any cardiovascular disease (CVD,
ICD-9: 390–459). Deaths of study subjects recruited at baseline in the years 1994/95 were ascer-
tained by regularly checking the vital status through population registries inside and outside
the study area until December 31rd, 2007. Death certificateswere obtained from local health
departments and coded for the underlying cause of death by a single trained person using the
9th revision of the International Classification of Diseases (ICD-9). In the analysis, events were
censored, if a subject died from a non-cardiovascular disease, was lost to follow-up, or was
alive at the end of the follow-up.
Natriuretic peptide measurements
After venipuncture, all samples were immediately centrifuged, transferred to Eppendorf-cups
on ice and frozen at -80° Celsius. No freezing or thawing cycles were performed until final mea-
surement. Measurements were taken from EDTA-plasma samples. BNP measurements have
been performed in 2001/2002 and NT-proBNP measurements in 2006. BNP and NT-proBNP
were assessed in all samples. Concentrations of plasma NT-proBNP were measured by an elec-
trochemiluminescence immunoassay (elecsys-proBNP, Roche Diagnostics, Risch, Switzer-
land). Plasma BNP was determined by standard immunoradiometric assay (Shionogi, Osaka,
Japan). To convert the unit of pg/ml to ng/l, multiply by 1.
Statistical methods
The current guidelines of the European Society of Cardiology for the diagnosis of chronic heart
failure recommend an exclusion cut-off point of plasma NT-proBNP of 125pg/ml for non-
acute patients suspected for heart failure[31]. To further assess the prognostic value of this cut-
off point, plasma NT-proBNP levels were dichotomized according to this threshold. To deter-
mine the best cut-off value of bloodNT-proBNP levels to predict CVD death in our study sam-
ple, the receiver operating characteristic (ROC) was computed. Additionally, plasma NT-
proBNP and BNP levels were analysed as continuous variables after natural logarithmic trans-
formation (logNT-proBNP, logBNP).
Cox multivariable proportional hazards models were performed to evaluate survival.
With CVD death being our main endpoint, we adjusted the multivariable regression analy-
sis for major cardiovascular risk factors in line with recent publications [3,4] and current guide-
lines of the American Heart Association [32]. Three regression models were employed: Model
I included age and sex as covariates; model II additionally controlled for clinical risk factors
(serum creatinine, hypertension, type 2 diabetes, bodymass index, BMI, ratio of total to high
density lipoprotein); model III extendedmodel II by adding LVMi, LA enlargement, early dia-
stolic dysfunction and EF.
Statistical significancewas assigned at a two-sided p-value of less than 0.05. All analyses
were carried out with SPSS statistics version 22 (IBM, Armonk, USA).
NT-proBNP as Independent Predictor of Mortality
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Results
Baseline characteristics
The analysed sample comprised of 1,223 participants with age, sex, baselinemeasurements of
NT-proBNP, baseline assessment of LVM and EF available. Participants’ baseline characteristics
are shown in Table 1. Mean age was 49.7±13.7 years and 51.3% of the participants were women.
Relevant LVH was detected in 43 (3.5%), and systolic LVD in 124 participants (10.1%).
NT-proBNP as predictor for cardiovascular mortality
First, we were interested whether our data could confirm the association of NT-proBNP with
CVD death. In a median follow-up time of 12.9 years (interquartile range, IQR, 0.4 years, mini-
mum 0.1 year, maximum 13.2 years), 52 of the 1,223 participants died from CVD. For these
52 persons, baseline NT-proBNP was significantly elevated compared to the surviving group
(median = 140.8 pg/ml, IQR = 351.0 pg/ml versus median = 51.3 pg/ml, IQR = 64.7 pg/ml,
p for difference = 7.710−30). The mortality according to the commonly used cut-point of
125pg/ml is depicted in Fig 1. A ROC analyses yielded a best cut-off value of bloodNT-proBNP
concentration to predict CVD death of 114.2pg/ml (sensitivity 60%, specifity 82%). In a Cox
regression model, the risk of CVD death was significantly increased by 67% per unit increase in
logNT-proBNP when adjusting for age and sex (model I, hazard ratio HR = 1.67, 95% confi-
dence interval, CI = [1.27, 2.21], p = 2.7810−4, Table 2). To derive the NT-proBNP effect on
CVD death independent of other cardiovascular risk factors, we further adjusted for serum cre-
atinine, hypertension, diabetes, BMI, and the ratio of total to high density lipoprotein (model
II) and found a similar effect (HR = 1.75, 95% CI = [1.33, 2.29], p = 5.1710−5). A comparison
of NT-proBNP with traditional cardiovascular risk factors is depicted in Fig 2.
NT-proBNP as predictor for mortality independent of cardiac
morphology and function
Second, we wanted to contribute to the debate on the explanation of the NT-proBNP associa-
tion with cardiovascularmortality. One explanation of this association is that NT-proBNP
Table 1. Baseline characteristics of the study sample.
Characteristics Men (n = 596) Women (n = 627)
Age [years] 49.8±13.9 49.6±13.5
Body-mass index [kg/m2] 26.8±3.2 26.4±4.6
Hypertension [%] 45.8 37.2
Diabetes [%] 4.6 3.6
Serum creatinine [mg/dl] 0.84±0.16 0.67±0.14
Total cholesterol [mg/dl] 234.2±43.6 231.3±44.2
High-density cholesterol [mg/dl] 48.0±14.0 60.0±16.6
Left atrial enlargement [%] 6.7 5.4
LVMi [g/m2] 96.3±22.3 81.8±19.9
E/A below 0.75 [%] 32.7 36.2
EF [%] 63.6±0.1 65.3±0.1
NT-proBNP [pg/ml] median (IQR) 38.1 (51.1) 66.9 (72.5)
BNP [pg/ml] median (IQR) 5.73 (9.76) 10.16 (11.14)
Shown are mean and standard deviation or proportions (if not indicated otherwise) for the 1,223 analysed
subjects separately for men and women.
Left atrial enlargement: left atrial volume index > 34ml/m2. LVMi: ratio of left ventricular mass to body surface
area. E/A: ratio of mitral valve E wave velocity divided by A wave velocity. EF: left ventricular ejection fraction
doi:10.1371/journal.pone.0164060.t001
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Fig 1. Cumulative survival to cardiovascular death. Kaplan-Meier curve for unadjusted cumulative
survival to cardiovascular death according to plasma NT-proBNP dichotomized by the exclusion cut-off point
of 125pg/ml recommended by the current guidelines of the European Society of Cardiology for the diagnosis
of chronic heart failure [31].
doi:10.1371/journal.pone.0164060.g001
Table 2. Increased relative risk for cardiovascular death by higher NT-proBNP levels.
Hazard Ratio 95% CI p-Value
Unadjusted 2.26 2.18 to 3.49 2.24*10−17
Model I 1.67 1.27 to 2.21 2.78*10−4
Model II 1.75 1.33 to 2.29 5.17*10−5
Model III 1.73 1.01 to 2.97 0.047
Shown are hazard ratio estimates for cardiovascular death per unit log NT-proBNP and P-values using the
Cox proportional hazard regression model without and with various adjustments. Analysed are 1,223
subjects with NT-proBNP measured at baseline including 52 deaths during a long-term follow-up (median
12.9 years, min = 0.1year, max = 13.2years) in a general population 25 to 74 years of age.
Model I: Adjustment for age and sex.
Model II (Clinical risk factors): Adjustment for age, sex, serum creatinine, hypertension, diabetes, BMI and
the ratio of total to high-density lipoprotein.
Model III (Clinical and echocardiographic risk factors): As Model II additionally adjusted for LVMi, EF and
signs of left ventricular diastolic dysfunction (left atrial enlargement, E/A ratio below 0.75).
doi:10.1371/journal.pone.0164060.t002
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detects subclinical cardiac adverse processes. Such processes often involve cardiac remodelling
and cardiac remodelling can be depicted by measuring LVM, signs of diastolic dysfunction and
EF. Therefore, we were interested whether our association of NT-proBNP with CVD death was
independent of LVM, LA enlargement, impaired E/A ratio and EF. We found that further
adjustment for LVMi, LA enlargement, E/A<0.75 and EF did not erase the significantly ele-
vated risk for CVD death by logNT-proBNP (model III, HR = 1.73, 95% CI [1.01, 2.97],
p = 0.047). Our data thus confirms a strong association of NT-proBNP and CVD death in a
general population study, which is independent of traditional cardiovascular risk factors and
traditional echocardiographicmeasurements for cardiac remodelling.
NT-proBNP and cardiovascular mortality in subgroups
Third, we investigated the observed association further in order to see whethermore could be
learned regarding the potential underlyingmechanism.While the Coxmodel adjusting for
covariates already removed the effects of the known cardiovascular risk factors and measures
of clinical cardiac remodelling, residual confounding can still be an issue. We thus comple-
mented the previous analyses by subgroup analysis restricting to subjects free of diseases, but
also conducted analyses separately for men and women and younger versus older adults.
Similar hazard ratio estimates were found for men and women (Table 3). For female sub-
jects, the association of baseline NT-proBNP blood levels and CVDmortality lost significance
which might be explained by few events (number of deaths = 13).
When separating the analysis for older versus younger, the cut-off was defined by the
median baseline age (70years) of the 52 participants who died for CVD during the follow-up
period.We found more pronounced hazard ratio estimates among the older.
Fig 2. Risk prediction for cardiovascular death by plasma NT-proBNP compared to common cardiovascular risk factors in the general
population. Shown are hazard ratio estimates for cardiovascular death adjusted for age and sex. NT-proBNP is dichotomized by the exclusion
cut-off point of 125pg/ml recommended by the current guidelines of the European Society of Cardiology for the diagnosis of chronic heart failure
[31]. Obesity: body-mass index > 30kg/m2. Relevant LVH: left ventricular mass to body surface area > 149g/m2 (men) / 122g/m2 (women). LVD:
systolic left ventricular dysfunction defined as ejection fraction below 55%.
doi:10.1371/journal.pone.0164060.g002
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When restricting the analysis to subjects free of diabetes (n = 1,149, number of deaths = 41),
NT-proBNP remained a significant and equally strong predictor of cardiovascular death
(HR = 1.70, 95% CI = [1.24, 2.31], p = 8.6910−4, Table 3). Quite similar results were found in
the subgroup (n = 998) free of obesity (HR = 1.69, 95%CI [1.23, 2.32], p = 1.0710−3, Table 3).
This supports the hypothesis that NT-proBNP’s role for death is not primarily due to subclini-
cal diabetes- or obesity-inducedprocesses.
Next, we defined a subgroup free of any LVH (LVMi < 115g/m2 in men; LVMi <95g/m2 in
women, n = 1,001, number of deaths = 26). In this subgroup, the risk for CVD death per unit
increase in logNT-proBNP (HR = 1.55) was similar to the risk increase in the entire study sam-
ple (HR = 1.67) albeit lower and now missing statistical significance (p = 0.087). The loss of sig-
nificancemight be due to a loss of power with only few deaths remaining in this subgroup. In a
less rigorously defined subgroup of “cardiac healthy” subjects just excluding relevant LVH
(LVMi < 149g/m2 in men; LVMi < 122g/m2 in women, n = 1,176; number of deaths = 42),
NT-proBNP persisted as strong and significant predictor of CVD death with similar hazard
ratio estimate (HR = 1.68, 95%CI = [1.22, 2.30], p = 1.3110−3).
When excluding subjects with LVD (EF< 55%, n = 1,097, number of deaths = 43), the asso-
ciation of baseline NT-proBNP with death remained significant, but the hazard ratio was
slightly attenuated (HR = 1.48, 95%CI [1.02, 2.14], p = 0.041).
In summary, effect estimates were very similar across all subgroup analyses with hazard
ratios between 1.48 and 1.70. Thus, it is unlikely that the association of NT-proBNP with death
was driven purely by either diabetes, obesity, LVH or LVD.
Table 3. Increased relative risk for cardiovascular mortality by log NT-proBNP even in the absence of relevant LVH or LVD.
N CVD death HR 95% CI p-value
Age  70 years 103 25 2.08 1.38; 3.15 4.80*10−4
< 70 years 1,120 27 1.40 0.92; 2.11 0.114
Sex Men 596 39 1.68 1.24; 2.28 8.73*10−4
Women 627 13 1.71 0.86; 3.39 0.125
Diabetes Present 49 10 1.56 0.72; 3.36 0.266
None 1,149 41 1.70 1.24; 2.31 8.69*10−4
Obesity Present 219 13 1.53 0.88; 2.65 0.129
None 998 39 1.69 1.23; 2.32 1.07*10−3
Any LVH Present 218 26 1.53 1.07; 2.20 0.021
None 1,001 26 1.55 0.94; 2.58 0.087
Relevant LVH Present 43 10 0.80 0.38; 1.70 0.567
None 1,176 42 1.68 1.22; 2.30 1.31*10−3
LVD Present 124 9 1.75 0.90; 3.40 0.097
None 1,097 43 1.48 1.02; 2.14 0.041
Any LVH or LVD Present 311 31 1.64 1.18; 2.28 3.60*10−3
None 906 21 1.03 0.58; 1.80 0.932
Diabetes or Obesity Present 451 36 1.63 1.20; 2.24 2.11*10−3
or any LVH or LVD None 754 15 0.95 0.49; 1.87 0.887
The analyses of Table 2 were repeated in subgroups defined by sex or age (adjusting by age or sex, respectively) and the presence or absence of
predefined cardiovascular risk factors (adjusted by age and sex) again applying a Cox proportional hazard regression model.
CVD death: death from cardiovascular diseases. HR: Adjusted hazard ratio of cardiovascular death per 1 unit increment in log(NT-proBNP) [ln pg/ml].
Obesity: body mass index > 30kg/m2. Any LVH: left ventricular hypertrophy defined as left ventricular mass to body surface area >115g/m2 (men) / 95g/m2
(women). Relevant LVH: left ventricular mass to body surface area > 149g/m2 (men) / 122g/m2 (women). LVD: systolic left ventricular dysfunction defined
as ejection fraction below 55%.
doi:10.1371/journal.pone.0164060.t003
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Plasma NT-proBNP and cardiovascular mortality in combined subgroups
Finally, we wanted to evaluate whether an analysis restricting to a very healthy subgroup still
exhibits the NT-proBNP association with CVD death. When excluding participants with any
LVH and LVD, NT-proBNP was not associated with CVD death and the effect was nearly
abolished (906 individuals, 21 CVD deaths, HR 1.03, P = 0.932). When additionally excluding
subjects with diabetes or obesity, we found similar results (754 subjects, 15 deaths, HR = 0.95;
p = 0.887). In order to understand these findings, we need to take the distribution of subjects
and the distribution of events (= CVD deaths) across the logNT-proBNP values into account
(Table A in S1 File). We see that few deaths occur in the very restricted subgroups defined by
the absence of diabetes, obesity, LVH and LVD. Additionally, logNT-proBNP values of 91.8%
of this very healthy group do not exceed 4.99 ln[pg/ml]. Thus, the lack of association in these
subgroup analyses can be due to a loss in power from sample size reduction and a reduction in
the variability of logNT-proBNP values in this subgroup (Table A in S1 File).
Sensitivity analyses using circulating BNP or all-cause mortality
As NT-proBNP and BNP values are highly correlated (Spearman coefficient r = 0.786;
p = 1.2210−256), but NT-proBNP levels are better measurable particularly for lower levels
(18.9% of BNP values below the lower detection limit in our study), we–as most authors–have
analysed NT-proBNP levels, despite the fact that BNP is the biologically active substance. Nev-
ertheless, we have repeated all analyses using BNP values and found a similar association of
increased BNP with CVD death (see Tables B and C in S1 File).
Furthermore, we have opted to focus on CVD death as outcome, as we are interested in the
cardiac mechanisms; other deaths would include a substantial portion of cancer deaths, which
have not been a focus here. However, for comparison to other previously published studies
using all-cause mortality, we have also conducted a sensitivity analysis including all deaths and
found similar results, with attenuated hazard ratios and similar P-values (Table D in S1 File).
Discussion
Our data confirmsNT-proBNP as strong predictor of cardiovascularmortality independent of
LVM, diastolic dysfunction and LVD in a large population-based study with long-term follow-
up. This supports the hypothesis that NT-proBNP predicts mortality even beyond traditional
measures of clinical LV remodelling and damage.
Previously published studies on NT-proBNP and risk of death
While there is a bulk of work on NT-proBNP in patients, there are only few studies on natriuretic
peptides as predictor of mortality in the general population (Table 4). Wang et al. (2004, Fra-
mingham) [3] has set the stage by showing that BNP predicts all-causemortality in the commu-
nity for the first time, and that this link persisted even with adjusting for basic measures of
cardiac remodelling.A lot of important and substantial work has been done by others to further
strengthenWang’s hypothesis. Not all of these confirmatory analyses have strictly population-
based designs or they have targeted composite endpoints: the so far largest study on this issue,
the PREVEND study [5], had enriched for study subjects with microalbuminuria, the KIHD
study [33] as well as the recently published CaPS study[34] focusedon men and the Copenhagen
study on the elderly above 55 years [35], albeit without availability of echocardiographic data.
Only two population-based studies–additional to ours—were able to evaluate echocardio-
graphic data and to estimate the mortality prediction by natriuretic peptides without and with
adjusting for cardiac remodelling (using a model adjusting for LVM and EF): the Framingham
NT-proBNP as Independent Predictor of Mortality
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Offspring study[3] by Wang and colleagues, already mentioned above, and the Rochester Epi-
demiologyProject Olmsted County cohort[4]. In these two studies, a random sample of the
general population was surveyedwith natriuretic peptide and LVM and EF measured at base-
line and followed to monitor vital status. This is a similar cohort study design as our KORA-S3
heart failure study.
Our study has a comparable number of all-cause deaths and extends these previous studies
by several further insights. Our subjects are on average about 10 years younger and cover a
Table 4. Published population-based studies investigating blood levels of natriuretic peptides as risk predictors for mortality.
Author Study Year of
publication
Number
of
subjects
Age
(mean
±SD)
[years]
Median
follow-
up
[years]
Natriuretic
peptide used
(additional
measured
peptide)
Outcome Number
of events
HR** P-value Echo data
Our study KORA-S3 1,223 49.7
±13.7
12.9 NT-proBNP
(BNP)
All-cause
mortality
99 1.43 0.001 LVM, EF,
LVD,
LAEn,
diastolic
function
CVD
death
55 1.67,
1.73†
<0.001,0.047†
Patterson
et al.
CaPS 2015 1,773
men
* 15.4 BNP CVD
death
355 1.54‡ <0.001‡ None
Linssen
et al.
PREVEND 2010 8,383 49±12.7 7.5 NT-proBNP All-cause
mortality
437 1.22 <0.001 None
Laukkanen
et al.
KIHD 2006 905 men 55.8±6.6 10 NT-proBNP
(NT-proANP)
All-cause
mortality
110 1.26 <0.001 None
CVD
death
58 1.41 <0.001
McKie et al. Olmsted
County
2006 1,991 62±10 5.6 NT-proBNP
(BNP)
All-cause
mortality
106 1.75,
1.44§
<0.001,
0.014§
LVM, LVD,
diastolic/
valvular
function,
LAEn,
RWMA
Kistorp
et al.
Copenhagen 2005 626 67.9
±10.6
5 NT-proBNP All-cause
mortality
94 1.55 0.001 None
Wang et al. Framingham
Offspring
2004 3,346 59±10
(men)/ 58
±10
(women)
5.2 BNP (NT-
proANP)
All-cause
mortality
119 1.27k 0.009k, 0.29¶ LVM, LVD,
LAEn
HR: hazard ratio per 1 unit increase in lnNT-proBNP (our study), per third of BNP distribution (CaPS), per 1 unit increase in log2NT-proBNP (PREVEND),
per 1SD-increment in log variable (KIHD, Olmsted, Copenhagen, Framingham). CVD: cardiovascular disease. LVM: left ventricular mass. EF: left
ventricular ejection fraction. LVD: left ventricular systolic dysfunction. LAEn: left atrial enlargement. RWMA: regional wall motion abnormalities.
* predominantly aged 55–69 at baseline.
** adjusted for age and sex (if not indicated otherwise).
† Adjustment for clinical risk factors and echo, in detail: age, sex, serum creatinine, ratio of total to high density lipoprotein, hypertension, diabetes, BMI,
LVMi, diastolic dysfunction, EF.
‡ adjusted for age, smoking, diabetes, systolic blood pressure, total cholesterol, total triglycerides, BMI, history of CVD, positive family history of coronary
heart disease.
§ Adjustment for clinical risk factors and echo, in detail: age, sex, serum creatinine, total cholesterol, hypertension, diabetes, coronary artery disease,
presence of EF <50%, diastolic dysfunction, valvular dysfunction, LVH, LAEn, RWMA.
k adjusted for age, sex, serum creatinine, ratio of total to high-density lipoprotein, hypertension, diabetes, BMI, smoking status.
¶ extends the adjustment of k by adding LVH, LVD, LAEn.
doi:10.1371/journal.pone.0164060.t004
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wider age-range of adult subjects. Thus, our confirmatory results are obtained in a younger and
potentially healthier study population. In addition, we may report the to date longest follow-up
period for this research question (KORA: median of 12.9 years; Framingham: 5.2 years[3];
Olmsted: 5.6 years[4]). We can particularly demonstrate a clear prognostic separation between
“normal” and “above-normal” NT-proBNP (>125pg/ml) in the general population. The sur-
vival curves do not start to separate until an observation period of> 5 years. Our data indicate
that NT-proBNP levels may predict cardiovascularmortality in a general adult population
more than a decade before the event. This makes NT-proBNP one of the most powerful predic-
tors for cardiovascularmortality that are easily obtainable even in general practice without
echocardiography. Additionally, we focused on cardiovascular death instead of including all-
cause mortality, as these are the deaths that we think are those of interest for a direct role of
NT-proBNP as supported by Linssen et al.[5] and our own sensitivity analysis. This makes our
study the first study in a general adult population being able to depict the prediction of NT-
proBNP with specificallyCVD death rather than all-causemortality.
Finally, the mitral E/A ratio was assessed by echocardiography. Thus, our data can show
that the association of NT-proBNP and CVD death in the general adult population is even
independent of very early signs of diastolic dysfunction.
On the debate of potential explanations why NT-proBNP predicts
mortality
It remains unclear why NT-proBNP is a predictor of all-cause mortality in the apparently
healthy, general population. In the PREVEND study, Linssen et al. found that the association
was predominantly with cardiovascular events and less with death of other causes, and thus
speculated that elevated NT-proBNP levels reflect silent myocardial diseases in the general
population[5], which might be conclusive for a cardiac hormone.
The initial hypothesis of the detection of inapparent cardiac disease as reason for the predic-
tive value of natriuretic peptides has been recently doubted by several further data. Natriuretic
peptide levels and the development of cardiovascular diseases seem to bemore complex and
interrelated than expected: experimental research showed BNP as cardiac hormone involved in
the development of several extra-cardiac diseases. For example, it directly affects vasculature
and metabolism [36,37]. Congruently, very recent epidemiologic studies have reported associa-
tions between natriuretic peptides and vascular diseases: in 2015, results from the Heinz-Nix-
dorf-Recall-study[7] and the Rotterdam study[8] ascertained a predictive value of NT-proBNP
for stroke and myocardial infarction. Bower et al. showed that NT-proBNP levels were associ-
ated with increased risk of hypertension in the ARIC cohort[38]. Also in 2015, new data from
ARIC revealed a strong association of NT-proBNP and abdominal aortic aneurysm as conse-
quence of atherosclerosis[39]. These considerable studies provided a substantial epidemiologic
link from natriuretic peptides to extramyocardial diseases, albeit all of these published studies
did unfortunately not control for cardiac processes by echocardiography. The Dallas Heart
Study [40] is one of two very interesting exceptions: a significant association was reported
betweenNT-proBNP levels and coronary artery calcium scores as marker of coronary artery
disease obtained by electron beam computed tomography. This association persisted after
adjustment for LVM and EF. In 2016, Pastormerlo and colleagues [9] published a case-control
study comparing asymptomatic subjects with hypertension and normotensive controls, where
they elaborated a significant association of NT-proBNP levels and carotid intima-media thick-
ness as well as coronary artery calcium score. By echocardiography they determined normal
mean values of EF, LVMi and diastolic dysfunction. Thus, these studies reinforced NT-proBNP
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as potential biomarker of preclinical atherosclerosis which could explain the association of
natriuretic peptides with CVD death independent of cardiac remodelling.
LVM, diastolic dysfunction and EF are considered as surrogate parameters of cardiac remod-
elling–irrespectiveof whether this cardiac remodelling processes are already associatedwith clini-
cal symptoms or not. Thus, if there is a direct link between natriuretic peptides and CVD leading
up to cardiac remodelling or even bypassing cardiac remodelling, the association of NT-proBNP
and CVD death should be independent of LVH, diastolic dysfunction and LVD. Indeed, we find
an association of NT-proBNP and BNP with CVD death adjusting for clinical cardiovascular risk
factors, LVM, signs of diastolic dysfunction and LVD. We can also report fairly stable risk esti-
mates when omitting one disease or condition at a time. A limitation of our work may be the fact
that echocardiographicmeasurementsmay lack precision in some uses[18] or the fact that unrec-
ognised confounders had an effect[41].However, removing those with relevant LVH at baseline
did not change the risk estimate; removingmore of those with either normal LVH or those with
left ventricular dysfunction decreased the risk estimate slightly. These results strengthen natri-
uretic peptides as risk predictor of cardiovascular death. Theymay integrate risks derived from
several cardiovascular risk states whichmight escape traditional echo quantification.
Strengths and limitations
A strength of our study is the population-based approach, the highly standardized procedures,
conduct by experienced, trained and quality controlled staff, and the particularly long follow-
up of more than a decade. Another strength is that echocardiography was conducted as part of
the study protocol, which makes it one of the few population-based studies that can relate
events happening a decade later to cardiac measurements at baseline.
We report a prevalence of 10.1% for systolic left ventricular dysfunctionwhich might appear
high for the rather young study population. As we intended to correct our analyses even for
very early manifestations of systolic LVD, we followed the very strict guidelines of 2005 defin-
ing systolic LVD as EF below 55%[30]. To ensure comparability with other definitions, we cal-
culated additionally the prevalence of systolic LVD in our study sample according to cut-offs
used by other large population-based samples (Table E in S1 File). The prevalence of systolic
LVD in our study is consistently lower than reported by the Rotterdam study[42], the Olmsted
County sample [4]and the Strong-Heart Study[43] which is in line with our population being
younger and more healthy.
Concerning the echocardiographicmeasurements our study is subject to the inherent limi-
tations of any of the few studies implying cardiovascular imaging technologies and exhibiting
such a follow-up period. Echocardiography was done according to current guidelines and
using the up-to-date equipment of 1994/1995. However, the current guidelines of the Ameri-
can Society of Echocardiography and the European Association of Cardiovascular Imaging
published in 2015 [26] still recommend the linear method to determine LVM as in 1994/1995
and reinforced this method for every-day screen and explicitly for large population studies as
published data did not state a clear advantage of another technique [44]. Hence, the LVM mea-
surement in 1994/1995 should not be a major drawback to define LVH.
Key structural alterations of diastolic dysfunction (LVH and LA enlargement) were assessed
according to the current heart failure [31] and echocardiographic guidelines [45]. For the
detection of very early diastolic dysfunctionwithout LA enlargement the E/A ratio was used as
proposed by Redfield [28] and implemented in current guidelines [16,45]. In our study, tissue
Doppler imaging was not conducted, which impedes the grading of diastolic dysfunction (I
°-III°). However, adjustment for diastolic dysfunction per se was possible and included in the
analyses.
NT-proBNP as Independent Predictor of Mortality
PLOS ONE | DOI:10.1371/journal.pone.0164060 October 6, 2016 12 / 16
Regarding the measurement of EF, the biplane method of disks is recommended by the
guidelines to accurately determine EF. We derived global LV function from linear M-Mode
measurements which is less precise in the presence of wall motion abnormalities than the rec-
ommendedmethod of disks. Last year’s guidelines concede that the older methodmay pro-
vides useful information in healthy subjects [26]. As only 6 of 1,223 participants in our study
reported a history of myocardial infarction, it should be a relatively healthy population with a
low prevalence of regional wall motion abnormalities. Thus, the shortcoming of lacking EF
determined by biplane method cannot be corrected but should play a minor role in the context
of this population based study.
Conclusion
Our data confirmsNT-proBNP and BNP as strong and independent predictors of cardiovascu-
lar disease death as well as all-causemortality during long-term follow-up in a large general
population-based study. Our study also indicates that this prediction is largely independent of
echocardiographic parameters of relevant cardiac remodelling and already occurs within and
slightly above the normal range. Our data strengthens the hypothesis that natriuretic peptides
monitor subtle preclinical cardiovascular processes very early on and beyond traditional echo-
cardiographic markers. Given our particularly long follow-up, we were able to depict NT-
proBNP as a predictor of death more than a decade before the event, which makes it one of the
most powerful predictors that can be easily obtained in general practice.
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